Antibiotic. Like Azithromycin, has off-target effect on mitochondrial ribosomes, components of which interact with the SARS-CoV-2 Nsp8 protein. Gordon et al. bioRxiv, Mar 23 2020, https://doi.org/10.1101/2020.03.22.002386.
- Datasheet: view or download
- Applications:Approved drug (U.S.) that could be repurposed
Biochemicals & reagents
1) Greer (2006) Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics; Proc. (Bayl. Univ. Med. Cent.) 19 155 2) Peterson (2008) A review of tigecycline – the first glycylcycline; Int. J. Antimicrob. Agents 32 Suppl 4 S215 3) Skrtic et al. (2011) Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia; Cancer Cell 20 674 4) Jia et al. (2016) Tigecyclin targets nonsmall cell lung cancer through inhibition of mitochondrial function; Fundam. Clin. Pharmacol. 30 297 5) Hu et al. (2016) Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner; Oncotarget 7 3171 6) D’Andrea et al. (2016) The mitochondrial translational machinery as a therapeutic target in Myc-driven lymphomas.; Oncotarget 7 72415 7) Chen et al. (2019) Inhibition of mitochondrial translation selectively targets osteosarcoma; Biochem. Biophys. Res. Commun. 515 9
Tigecycline is a clinically useful antibiotic (1,2). It is a glycylcycline derivative of minocycline that binds to the 30S ribosomal subunit of bacteria blocking the interaction of aminoacyl-tRNA with the ribosome. This antobiotic is active against Gram-positive and -negative bacteria, anaerobic bacteria and drug resistant bacteria such as MRSA, MRSE, and VRE. It has also been shown to be selectively toxic to human acute myeloid leukemia cells over normal hematopoietic cells via inhibition of mitochondrial protein translation (3). It has also been found to be effective against other cancers including non-small cell lung cancer (4), melanoma (5), lymphoma (6) and osteosarcoma (7).